Cytori Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CYTX and buy or sell other stocks, ETFs, and their options commission-free!

About CYTX

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. 

CEO
Marc H. Hedrick, MD, MBA
CEOMarc H. Hedrick, MD, MBA
Employees
Employees
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
1996
Founded1996
Employees
Employees

CYTX Key Statistics

Market cap
42.13M
Market cap42.13M
Price-Earnings ratio
-0.19
Price-Earnings ratio-0.19
Dividend yield
Dividend yield
Average volume
275.70K
Average volume275.70K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$23.43
52 Week high$23.43
52 Week low
$2.90
52 Week low$2.90

Stock Snapshot

With a market cap of 42.13M, Cytori Therapeutics(CYTX) trades at $3.56. The stock has a price-to-earnings ratio of -0.19.

Cytori Therapeutics(CYTX) stock opened on 2026-05-01 at —. The price climbed to — and dipped to —.

Cytori Therapeutics(CYTX) shares are trading with a volume of 0, against a daily average of 275.7K.

In the last year, Cytori Therapeutics(CYTX) shares hit a 52-week high of $23.43 and a 52-week low of $2.90.

In the last year, Cytori Therapeutics(CYTX) shares hit a 52-week high of $23.43 and a 52-week low of $2.90.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.